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A 50-year-old man has been in your intensive care unit (ICU)
for 10 days. He was initially admitted with respiratory failure
secondary to congestive heart failure. Since admission he has
been intubated and mechanically ventilated. His progress in
the ICU has been relatively slow as a result of a variety of minor
setbacks. Finally, his condition seems to be improving and you
have started the weaning process. On your rounds, you identify
a new temperature and purulent secretions that are being
suctioned from his endotracheal tube. The chest X-ray also
shows a new infiltrate. You suspect VAP and you need to
decide whether to perform a bronchoscopy to assist you with
making a diagnosis and guiding future antibiotic choice.
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Abstract
Although mechanical ventilation is instituted as a life-saving technique, it may lead to complications that
can negatively impact on patients’ morbidity and/or mortality. Ventilator associated pneumonia (VAP) is
one such complication that is a common challenge to intensivists. Although most experts would agree
that early ‘appropriate’ antibiotic use is essential in patients who develop VAP, the best diagnostic test
to guide decision-making is far from clear. One diagnostic test that is capable of providing
microbiological samples from the lower respiratory tree is invasive bronchoscopy with a protected
specimen brush. Such a procedure has long been available to intensivists and is frequently employed
in many intensive care units. However, this procedure has associated costs and potential
complications, and its utility in VAP has been challenged. In this issue of Critical Care Forum, the two
sides of this debate are brought forward with compelling arguments. The authors’ arguments should
fuel future trials.
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The scenario
Pro: a protected specimen brush should be used in the diagnosis of VAP
Daren Heyland
Given the absence of a true ‘gold standard’, discussions
about the sensitivity and specificity of various diagnostic
techniques for VAP are not illuminating. However, a question
still remains: Does a management strategy that incorporates
the results from invasive diagnostic tests lead to important
differences in patient management and improved outcomes
compared with results from endotracheal aspirates? This
important question cannot be answered without examining
issues related to antibiotic use.
For a patient with VAP, what is probably more important to
the final outcome than the diagnostic test is the use ofCritical Care    April 2002 Vol 6 No 2 Heyland et al.
appropriate broad spectrum empiric antibiotics. Several
studies have documented that patients with a suspicion of
VAP who receive inadequate empiric antibiotic therapy are
more likely to die or experience complications [1,2]. The use
of broad spectrum antibiotics as the initial management of
suspected VAP is likely to result in less microbiologic failure
and improved clinical outcomes. However, the overuse or
indiscriminate use of broad spectrum antibiotics is implicated
in the development of infections due to multiresistant bacteria
and fungi [3,4]. The primary strategy for preventing antibiotic-
resistant nosocomial infections is eliminating or reducing the
unnecessary use of antibiotics [5]. Several studies have
demonstrated that narrowing the spectrum of antibiotics
and/or discontinuing antibiotics are more probable with the
use of bronchoscopy with quantitative cultures [6–8]. The
same cannot be said for quantitative cultures from
endotracheal aspirates.
Do invasive diagnostic tests influence patient outcomes? A
recent randomized trial suggested that patients managed
according to results from invasive tests had a lower mortality
at 14 days (16.2% versus 25.8%, P = 0.022) compared with
patients who underwent endotracheal aspiration [8]. Mortality
rates were similar in both groups at 28 days. In this study [8],
the non-standardized antibiotic administration represents an
important confounding variable. The choice of individual
antibiotics was left to the attending physician, who was to
follow the American Thoracic Society Consensus
Conference guidelines on antibiotic therapy [9]. Using these
guidelines can result in several different combinations of
antibiotics. There was a much lower rate of inappropriate
empiric antibiotics in the group that underwent invasive
testing (0.5% versus 13%, P < 0.001). Thirty-two percent of
patients with inappropriate empiric antibiotics died compared
with 20.4% of patients who received appropriate initial
therapy (P > 0.02). Of the cohort receiving inappropriate
antibiotics, 33% died (all in the non-invasive group) before
day 14. It is plausible that the mortality difference between
the two groups had less to do with the diagnostic strategy
and more to do with the antibiotic choices.
In conclusion, the potential advantage of using invasive
techniques is that antibiotic therapy may be tailored to the
results of diagnostic tests. This may reduce unnecessary
broad spectrum antibiotics, which could have important
clinical implications, such as minimizing the emergence of
resistant microorganisms in the ICU and reducing antibiotic
costs.
Con: a protected specimen brush should not be used in the diagnosis of VAP
Santiago Ewig and Antoni Torres
There is no doubt that clinical symptoms, laboratory results,
and chest radiographs are only of limited value in establishing
the diagnosis of VAP, thereby mounting a considerable risk
of antimicrobial overtreatment [10]. The key question is
whether independent microbiological criteria are able to
correct for the bias arising from clinical judgment.
Of all diagnostic techniques, the bronchoscopic protected
specimen brush (PSB) has been studied most extensively.
Theoretically, the double catheter and the distal plug design
should preserve a very high specificity. On the contrary, since
the PSB samples a very small amount of respiratory
secretions (about 0.01–0.001 ml), it is expected to yield a
relatively limited sensitivity. The results of clinical studies
evaluating the PSB technique have in fact been conflicting,
with wide variations of operative indices being a striking
feature. Overall, false-negative and false-positive results were
reported in 10–40% of cases [11–15].
Differing references and thresholds for the calculation of
diagnostic indices account for a large part of these variations
[15]. Moreover, the PSB technique exhibits a considerable
variability. One study could demonstrate that the qualitative
repeatability was 100%, whereas in 59% of the patients the
quantitative results varied by more than 1 log10, with 14%
spreading out on each side of the chosen threshold [16]. In
addition, several problems inherent to the evaluation of
acutely ill patients do have a significant bearing on the
interpretation of PSB results. Reasons for false-negative
results include sampling errors owing to the multifocal
evolution of VAP, prior antimicrobial treatment, and borderline
results in an early stage of infection. Reasons for false-
positive results include contamination of the sample during
bronchoscopy or in the processing laboratory, colonization
rather than infection, and bronchiolitis [15].
Several investigations have been performed using
postmortem histology or lung culture as an independent
reference [17–21]. The postmortem model added
significantly to our understanding of the relationships of
histology and microbiology, and to the diagnosis of VAP.
Nevertheless, as regards operative indices, roughly the same
results were obtained as in studies without strictly
independent references. Of concern, it became evident that
whereas the reported results strongly depend on the
reference used, no reference is irrefutable. An important
clinical inplication was a comparable yield of bronchoscopic
diagnostic tools, such as PSB and broncho-alveolar lavage
(BAL), as well as of invasive and non-invasive techniques in
most studies.
In view of these findings, it seems unlikely that PSB (and/or
BAL) could have an advantage over non-invasive tools in
terms of clinical outcomes. Overall, four corresponding
randomized studies have so far been published evaluating
non-invasive and invasive diagnostic tools [7,8,22,23].Available online http://ccforum.com/content/6/2/117
Pro’s response
Daren Heyland
I have not suggested that we ‘rely on microbiological data
[from bronchoscopic specimens] as an independent reference
standard’. Microbiological data, from whatever source, need to
be incorporated as a variable in a complex equation that
considers other patient characteristics to determine the
likelihood of pneumonia. ‘Pulmonary infection scores’ have not
been properly validated, and suggesting the use of them is not
consistent with current evidence. I posit that sufficient
evidence exists to conclude that bronchoscopy can help
clinicians manage the use of broad spectrum antibiotics more
appropriately. Whether bronchoscopy influences patient
outcomes remains to be determined. When completed, a
multicenter randomized trial being conducted by the Canadian
Critical Care Trials Group will provide the definitive answer.
Whereas all Spanish studies [7,22,23] could not find any
difference with regard to outcome measures (such as length
of hospitalization, length of ICU stay, length of intubation,
mortality, and costs), the multicenter French study [8] found a
bronchoscopic strategy including quantitative cultures of
PSB and/or BAL to be superior compared with a clinical
strategy using qualitative tracheobronchial aspirates in terms
of 14-day mortality, morbidity, and use of antimicrobial
treatment.
Differences in study design may again have accounted for
most of the differences. In our view, however, it is unclear
from the French study data how the invasive strategy
accounted for the better outcome. Moreover, the clinical
group had a significantly higher rate of patients with
inadequate antimicrobial treatment [8]. Finally, since the
French study compared inhomogeneous strategies (a
bronchoscopic approach with quantitative cultures versus a
clinical approach with qualitative cultures), it does not allow
us to make any conclusions about the value of invasive
bronchoscopic tools as compared with the quantitative
tracheobronchial aspirate [24]. In our recent randomized
study evaluating the impact of diagnostic techniques on the
outcome, we could not find any difference in outcome when
quantitative tracheobronchial aspirates were compared with
a bronchoscopic strategy [23].
What therefore is the role of PSB in clinical practice? We
argue that currently available data do not support a regular
bronchoscopic approach to the diagnosis of suspected VAP.
Relying on microbiological data as an independent reference
would clearly introduce a new bias; we could show that the
microbiological correction of false-positive clinical judgments
is countered by the misclassification of correctly positive
judgments [25].
Instead, we support an approach that is based on extended
clinical criteria (including not only the classical four criteria as
defined by Johanson [26], but also the Clinical Pulmonary
Infection Score [27]) and quantitative cultures of
tracheobronchial aspirates. In this approach, microbiological
data do not form independent criteria for the diagnosis of
VAP, but support a clinical decision that inevitably is not fully
standardized and is open to bias. The selection of an
antimicrobial regimen should be based on local microbial and
resistance patterns.
New investigational concepts that define subgroups of low-
risk patients in whom antimicrobials may be stopped after 3
days, and that hint at reducing the antimicrobial selection
pressure by reducing the time of exposure to and by
introducing crop rotation of antimicrobials, are in line with our
approach [28–30]. The bronchosopic investigation would
then be regarded as a second-line target in case of a failure
to respond to empiric antimicrobial treatment. In these
patients, several conditions favor the use of bronchoscopic
techniques: PSB in combination with BAL; a higher pretest
probability of VAP; a higher probability of drug-resistant
pathogens; and the possible presence of opportunistic
pathogens, non-infectious mimics, and specific
tracheobronchial conditions that require a visualization of the
tracheobronchial tree [15].
Con’s response
Santiago Ewig and Antoni Torres
We respond with two points. First, given the failure of any
diagnostic tool to independently establish the presence of
VAP, no tool is helpful in reducing ‘unnecessary’ broad
spectrum antimicrobial treatment. Treatment decisions must
still be based on both clinical and microbiological data.
Second, given the comparable yield of quantitative PSB/BAL
and tracheobronchial aspirates in the detection of potentially
pathogenic microorganisms, antimicrobial treatment may be
satisfactiorily tailored according to general microbial and
susceptibility patterns prevalent in a given institution and to
the results of quantitative tracheobronchial aspirates in the
individual patient.Critical Care    April 2002 Vol 6 No 2 Heyland et al.
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